Bristol-Myers Squibb Poised for In-Line Q1 Amid One-Off Volatility, RBC Says
Bristol-Myers Squibb's (BMY) Q1 results are expected to come in line with consensus, but weaker oncology sales and one-off factors are likely to give way to volatility, RBC Capital Markets said Friday in a note.The investment firm said the quarter will be difficult to model due to volatility from destocking patterns, tough year-over-year comparisons, policy impacts and generic phasing dynamics.RBC said it estimates the company to report Q1 revenue of $10.75 billion and earnings of $1.42 per share. Analysts polled by FactSet expect $1.42 in non-GAAP EPS, $1.17 in GAAP EPS and $10.87 billion in revenue.Investor focus during the quarterly call will be on the company's upcoming trial results, particularly late-stage data for drug candidates milvexian and cobenfy, which are key to determining when Bristol-Myers returns to growth.Bristol-Myers will report Q1 results on April 30.RBC has a sector perform rating and price target of $60 on the stock.Price: $58.62, Change: $-0.85, Percent Change: -1.44%